Journal article
Five computational developability guidelines for therapeutic antibody profiling
- Abstract:
-
Therapeutic mAbs must not only bind to their target but must also be free from “developability issues” such as poor stability or high levels of aggregation. While small-molecule drug discovery benefits from Lipinski’s rule of five to guide the selection of molecules with appropriate biophysical properties, there is currently no in silico analog for antibody design. Here, we model the variable domain structures of a large set of post-phase-I clinical-stage antibody therapeutics (CSTs) and calc...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 858.8KB)
-
(Version of record, pdf, 3.5MB)
-
(Version of record, xlsx, 12.2KB)
-
(Version of record, xlsx, 45.8KB)
-
(Version of record, xlsx, 22.3KB)
-
- Publisher copy:
- 10.1073/pnas.1810576116
Authors
Bibliographic Details
- Publisher:
- National Academy of Sciences Publisher's website
- Journal:
- Proceedings of the National Academy of Sciences Journal website
- Volume:
- 116
- Issue:
- 10
- Pages:
- 4025-4030
- Publication date:
- 2019-02-14
- Acceptance date:
- 2019-01-10
- DOI:
- EISSN:
-
1091-6490
- ISSN:
-
0027-8424
- Source identifiers:
-
967532
Item Description
- Keywords:
- Pubs id:
-
pubs:967532
- UUID:
-
uuid:8a952eb2-108c-4a19-b181-bb9f89b4727c
- Local pid:
- pubs:967532
- Deposit date:
- 2019-01-31
Terms of use
- Copyright holder:
- Raybould et al
- Copyright date:
- 2019
- Notes:
-
Copyright © 2019 the Authors. Published by PNAS.
This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record